HIV-2 Integrase Resistance to Raltegravir
Author Information
Author(s): Ni Xiao-Ju, Delelis Olivier, Charpentier Charlotte, Storto Alexandre, Collin Gilles, Damond Florence, Descamps Diane, Mouscadet Jean-François
Primary Institution: LBPA, CNRS, Ecole Normale Supérieure de Cachan, Cachan, France
Hypothesis
HIV-2 resistance to raltegravir involves specific mutations in the integrase coding region.
Conclusion
The study confirms that HIV-2 resistance to raltegravir is primarily due to the N155H, G140S/Q148R, or E92Q/Y143C mutations.
Supporting Evidence
- HIV-2 is less sensitive to some protease inhibitors and has limited treatment options compared to HIV-1.
- The study identified three main mutation patterns associated with resistance to raltegravir in HIV-2.
- N155H and G140S/Q148R mutations were confirmed to confer resistance to raltegravir.
Takeaway
Some changes in the HIV-2 virus can make it resistant to a medicine called raltegravir, which is used to treat HIV.
Methodology
The study involved amplifying the integrase coding sequence from plasma samples of HIV-2 infected patients and assessing the susceptibility of integrases to raltegravir.
Limitations
The study does not explore all possible mutations that could affect resistance.
Participant Demographics
Patients included three RAL-naive and seven RAL-treated individuals infected with HIV-2.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website